Summary

The global synthetic biology market is projected to surpass USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a significant CAGR of 20.6%. The excessive demand for bio-based products is providing momentum to the market growth. Furthermore, rising investment by key market players and increasing funding in R&D & collaborations in the synthetic biology market to meet the needs of both local and international markets is further driving the market growth. The development of CRISPR and other gene-editing technologies opened new avenues for the synthetic biology sector. These advanced technologies enable precise gene modifications, accelerating advancements in therapeutic applications and agriculture fueling the growth of the synthetic biology market.
“The oligonucleotide & synthetic DNA synthetic biology segment accounted for the highest share in 2023.”
On the basis of tools, the synthetic biology market is further segmented into xeno nucleic acids, enzymes, chassis organisms, cloning technology kits, oligonucleotides and synthetic DNA, and synthetic cells. The oligonucleotides and synthetic DNA dominated the market and anticipated to grow at a significant CAGR during the forecast period. Rise in the use of oligonucleotides and synthetic DNA in environmental, food, and industrial sectors, expansion of synthetic biology companies in in areas such as agriculture, energy, and industrial biotechnology are some of the major factors driving the segmental growth.
“By applications, medical applications segment accounted for the largest share in the synthetic biology market.”
The applications segment in the synthetic biology market is segmented into medical applications, industrial applications, food, animal health & agricultural applications and environmental applications. The medical applications segment dominated the market share owing to the increasing prevalence of chronic diseases and genetic disorders which is driving demand for innovative medical solutions. Furthermore, with advancements in gene editing and synthetic microbes, researchers can develop targeted therapies, personalized medicine, and even engineered vaccines.
“North America: the largest share of the synthetic biology market”
By region, the market is segment into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the synthetic biology market in 2023 and is estimated to continue dominance during the forecast period. Presence of dominant market players in pharmaceutical and biotechnological companies in the region, strong base of synthetic biology manufacturers such as Thermo Fisher Scientific Inc. and Agilent Technologies Inc. are some of the prominent factors acerating market growth.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the synthetic biology market.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Novozymes A/S (Denmark), Agilent Technologies Inc. (US), Eurofins Scientific (Luxembourg), Amyris, Inc. (US), Twist Bioscience (US), Codexis, Inc. (US), Genscript (US), Ginkgo Bioworks (US), Precigen (US), Creative Enzymes (US), Synthego (US), Viridos (US), and Cyrus Biotechnology (US) are some of the major players operating in the synthetic biology market.

Research Coverage:
This research report categorizes the synthetic biologys market tools (oligonucleotides & synthetic DNA, enzymes, cloning technology kits, chassis organisms, xeno nucleic acids and synthetic cells), technologies (measurement and modeling, genome engineering, gene synthesis, cloning, site-directed mutagenesis, microfluidics, sequencing, nanotechnology and bioinformatics), and applications (medical applications, industrial applications, food, animal health & agricultural applications and environmental applications) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the synthetic biologys market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the synthetic biology market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the synthetic biology and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (diverse applications of synthetic biology, increasing demand for bio-based products, advancements in synthetic biology, rising funding in R&D and collaborations), restraints (production scalability, ethical and regulatory challenges), opportunities (rising opportunities for agricultural synthetic biology, growing use of artificial intelligence and machine learning) and Challenges (Cost constraints) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on upcoming technologies in synthetic biology manufacturing, research and development activities, and new product launches in the synthetic biology market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the synthetic biology market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Novozymes A/S (Denmark), Eurofins Scientific (Luxembourg), Agilent Technologies Inc. (US), among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 45
1.1 STUDY OBJECTIVES 45
1.2 MARKET DEFINITION 45
1.3 STUDY SCOPE 46
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 46
1.3.2 INCLUSIONS AND EXCLUSIONS 47
1.3.3 YEARS CONSIDERED 47
1.3.4 CURRENCY CONSIDERED 47
1.4 STAKEHOLDERS 48
1.5 SUMMARY OF CHANGES 48
2 RESEARCH METHODOLOGY 49
2.1 RESEARCH DATA 49
2.1.1 SECONDARY DATA 50
2.1.2 PRIMARY DATA 51
2.2 MARKET ESTIMATION METHODOLOGY 52
2.2.1 MARKET SIZE ESTIMATION 52
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 54
2.2.3 TOP-DOWN APPROACH 55
2.3 MARKET GROWTH RATE PROJECTION 56
2.4 DATA TRIANGULATION 58
2.5 RESEARCH ASSUMPTIONS 59
2.6 RESEARCH LIMITATIONS 60
2.7 RISK ANALYSIS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 65
4.1 SYNTHETIC BIOLOGY MARKET OVERVIEW 65
4.2 NORTH AMERICA: SYNTHETIC BIOLOGY MARKET, BY APPLICATION
AND COUNTRY (2023) 66
4.3 SYNTHETIC BIOLOGY MARKET SHARE, BY APPLICATION, 2024 VS. 2029 67
4.4 SYNTHETIC BIOLOGY MARKET, BY REGION 67
 
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
5.2.1 DRIVERS 69
5.2.1.1 Diverse applications of synthetic biology 69
5.2.1.2 Surging demand for bio-based products 70
5.2.1.3 Advancements in synthetic biology 70
5.2.1.4 Increasing funding in R&D and collaborations 71
5.2.2 RESTRAINTS 73
5.2.2.1 Production scalability 73
5.2.2.2 Ethical and regulatory challenges 74
5.2.3 OPPORTUNITIES 75
5.2.3.1 Rising opportunities for agricultural synthetic biology 75
5.2.3.2 Growing integration of artificial intelligence and machine learning 76
5.2.4 CHALLENGES 76
5.2.4.1 Cost constraints 76
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 77
5.4 VALUE CHAIN ANALYSIS 78
5.5 ECOSYSTEM ANALYSIS 80
5.5.1 PRODUCT/SERVICE PROVIDERS 80
5.5.2 END USERS 82
5.5.3 REGULATORY LANDSCAPE 82
5.6 TECHNOLOGY ANALYSIS 83
5.6.1 KEY TECHNOLOGIES 83
5.6.1.1 DNA synthesis and sequencing 83
5.6.1.2 Gene editing tools 84
5.6.1.3 Bioinformatics and computational tools 84
5.6.1.4 Nanotechnology 85
5.6.2 COMPLEMENTARY TECHNOLOGIES 86
5.6.2.1 Cellular and tissue engineering 86
5.6.3 ADJACENT TECHNOLOGIES 87
5.6.3.1 Metabolic engineering 87
5.7 PATENT ANALYSIS 87
5.7.1 METHODOLOGY 87
5.7.2 NUMBER OF PATENTS FILED 87
5.7.3 INNOVATION AND PATENT APPLICATIONS 88
5.8 PRICING ANALYSIS 90
5.8.1 INDICATIVE PRODUCT PRICING ANALYSIS, BY KEY PLAYER 90
5.8.2 INDICATIVE PRODUCT PRICING ANALYSIS, BY REGION 91
5.9 KEY CONFERENCES & EVENTS, 2024–2025 92
 
5.10 REGULATORY LANDSCAPE 93
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
5.10.2 REGULATORY FRAMEWORK 96
5.11 INVESTMENT & FUNDING SCENARIO 97
5.12 PORTER’S FIVE FORCES ANALYSIS 98
5.12.1 INTENSITY OF COMPETITIVE RIVALRY 99
5.12.2 BARGAINING POWER OF SUPPLIERS 99
5.12.3 BARGAINING POWER OF BUYERS 99
5.12.4 THREAT OF SUBSTITUTES 99
5.12.5 THREAT OF NEW ENTRANTS 99
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 100
5.13.1 KEY BUYING CRITERIA 101
5.14 IMPACT OF AI ON SYNTHETIC BIOLOGY MARKET 102
6 SYNTHETIC BIOLOGY MARKET, BY TOOL 104
6.1 INTRODUCTION 105
6.2 OLIGONUCLEOTIDES & SYNTHETIC DNA 105
6.2.1 SURGING DEMAND FOR SYNTHETIC GENES TO SUPPORT MARKET GROWTH 105
6.3 ENZYMES 109
6.3.1 WIDE POTENTIAL OF ENZYME ENGINEERING IN OMICS STUDIES
TO PROPEL MARKET 109
6.4 CLONING TECHNOLOGY KITS 113
6.4.1 ALTERATION AND OPTIMIZATION OF GENETIC CIRCUIT DESIGNS
BY MOLECULAR BIOLOGY TECHNIQUES TO DRIVE MARKET 113
6.5 SYNTHETIC CELLS 116
6.5.1 GROWING POPULARITY OF SYNTHETIC CELLS AS SUBSTITUTES FOR NATURAL CELLS TO BOOST MARKET GROWTH 116
6.6 CHASSIS ORGANISMS 121
6.6.1 INCREASING DEMAND FOR FOSSIL FUELS TO PROPEL MARKET 121
6.7 XENO NUCLEIC ACIDS 124
6.7.1 SPIKE IN DEMAND FOR BREAKTHROUGH MEDICINES TO
AID MARKET GROWTH 124
7 SYNTHETIC BIOLOGY MARKET, BY TECHNOLOGY 128
7.1 INTRODUCTION 129
7.2 GENE SYNTHESIS 129
7.2.1 RISING DEMAND FOR SYNTHETIC GENES AND INCREASING COMPETITIVENESS AMONG MARKET PLAYERS TO SPUR MARKET GROWTH 129
7.3 GENOME ENGINEERING 134
7.3.1 SURGING NEED FOR RAPID, CHEAP, AND MULTIPLEX MODIFICATION OF GENOMES TO DRIVE MARKET 134
 
7.4 SEQUENCING 138
7.4.1 RISING ADOPTION OF SEQUENCING TECHNOLOGY TO
BOOST MARKET GROWTH 138
7.5 BIOINFORMATICS 142
7.5.1 INCREASING ADVANCEMENTS AND RISING USE OF BIOINFORMATICS TO PROPEL MARKET GROWTH 142
7.6 CLONING 145
7.6.1 PRECISE GENETIC REPLICATION TO ACCELERATE RESEARCH AND
SCALING APPLICATIONS ACROSS VARIOUS INDUSTRIES 145
7.7 SITE-DIRECTED MUTAGENESIS 149
7.7.1 WIDE APPLICATIONS IN GENETIC ENGINEERING, DNA ASSEMBLY, AND CLONING TECHNOLOGIES TO DRIVE MARKET 149
7.8 MEASUREMENT & MODELING 152
7.8.1 INCREASING DEMAND FOR CELL-FREE SYNTHETIC BIOLOGY TO
FOSTER MARKET GROWTH 152
7.9 MICROFLUIDICS 156
7.9.1 RISING FOCUS ON INCREASING SCALABILITY OF SYNTHETIC BIOLOGY TOOLS TO PROPEL MARKET GROWTH 156
7.10 NANOTECHNOLOGY 159
7.10.1 CONVERGENCE BETWEEN SYNTHETIC BIOLOGY AND NANOTECHNOLOGY TO AID MARKET GROWTH 159
8 SYNTHETIC BIOLOGY MARKET, BY APPLICATION 163
8.1 INTRODUCTION 164
8.2 MEDICAL APPLICATIONS 164
8.2.1 PHARMACEUTICALS 168
8.2.1.1 Potential of synthetic biology techniques in development of active pharmaceutical ingredients to drive market 168
8.2.2 DRUG DISCOVERY & THERAPEUTICS 172
8.2.2.1 Cancer detection & diagnostics 176
8.2.2.1.1 Increasing investments in cancer research to
support market growth 176
8.2.2.2 Other drug discovery & therapeutic applications 179
8.2.3 ARTIFICIAL TISSUE & TISSUE REGENERATION 183
8.2.3.1 Biosynthesis 187
8.2.3.1.1 Expansive design space enabled by synthetic biology to foster market growth 187
8.2.3.2 Stem cell regulation 190
8.2.3.2.1 Stem cell research to accelerate market growth 190
8.2.3.3 Other artificial tissue & tissue regeneration applications 194
8.3 INDUSTRIAL APPLICATIONS 197
8.3.1 BIOFUELS & RENEWABLE ENERGY 202
8.3.1.1 Advantages of using genetically engineered organisms for synthetic production of biofuels to propel market growth 202
 
8.3.2 INDUSTRIAL ENZYMES 205
8.3.2.1 Textile industry 209
8.3.2.1.1 Surge in demand for increasing reaction rates and reducing costs to foster market growth 209
8.3.2.2 Paper industry 213
8.3.2.2.1 Increasing use of enzymes in pulp and paper industry to favor market growth 213
8.3.2.3 Consumer care industry 216
8.3.2.3.1 Skincare & cosmetics 221
8.3.2.3.1.1 Benefits offered by synthetic biology technologies in manufacturing of skincare and cosmetic products to propel market growth 221
8.3.2.3.2 Other consumer care products 224
8.3.2.4 Other industries 228
8.3.3 BIOMATERIALS & GREEN CHEMICALS 231
8.3.3.1 Production of green chemicals through microbial fermentation to drive market 231
8.4 FOOD, ANIMAL HEALTH, AND AGRICULTURAL APPLICATIONS 234
8.4.1 FLAVORS & FRAGRANCES 239
8.4.1.1 Rising demand for natural, sustainable products to
bolster market growth 239
8.4.2 OTHER FOOD, ANIMAL HEALTH, AND AGRICULTURAL APPLICATIONS 242
8.5 ENVIRONMENTAL APPLICATIONS 246
8.5.1 BIOREMEDIATION 250
8.5.1.1 Increasing need for cost-effective, on-site environmental monitoring methods to boost market 250
8.5.2 BIOSENSING 253
8.5.2.1 Growing interest in development of whole-cell biosensors
to drive market 253
9 SYNTHETIC BIOLOGY MARKET, BY REGION 257
9.1 INTRODUCTION 258
9.2 NORTH AMERICA 258
9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 266
9.2.2 US 267
9.2.2.1 Rising investment in synthetic biology companies and surging demand for bio-based products to drive market 267
9.2.3 CANADA 273
9.2.3.1 Strong research infrastructure and availability of funding to
support market growth 273
9.3 EUROPE 278
9.3.1 EUROPE: MACROECONOMIC OUTLOOK 284
9.3.2 GERMANY 285
9.3.2.1 Government initiatives and increasing funding to propel
market growth 285
 
9.3.3 UK 291
9.3.3.1 Increasing R&D expenditure to favor market growth 291
9.3.4 FRANCE 297
9.3.4.1 Investments aimed at increasing research in various biomedical fields to augment market growth 297
9.3.5 SWITZERLAND 302
9.3.5.1 Established biotech ecosystem, strong academic institutions, and favorable government policies to favor market growth 302
9.3.6 DENMARK 307
9.3.6.1 Presence of third-largest commercial drug development pipeline in Europe to favor market growth 307
9.3.7 ITALY 312
9.3.7.1 Increasing life sciences R&D funded by both public and private organizations to foster market 312
9.3.8 SPAIN 317
9.3.8.1 Well-established network of research centers, universities, and hospitals to support market growth 317
9.3.9 REST OF EUROPE 322
9.4 ASIA PACIFIC 328
9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 335
9.4.2 CHINA 336
9.4.2.1 Rising growth opportunities for pharmaceutical and biopharmaceutical companies to drive market 336
9.4.3 JAPAN 342
9.4.3.1 Growing awareness of synthetic biology's importance and potential applications to accelerate market growth 342
9.4.4 INDIA 347
9.4.4.1 Increasing R&D activities and government funding initiatives to bolster market growth 347
9.4.5 AUSTRALIA 353
9.4.5.1 Increasing funding for synthetic biology research to
accelerate market growth 353
9.4.6 SOUTH KOREA 358
9.4.6.1 Increasing focus on developing biotechnology and pharmaceutical sectors to boost market 358
9.4.7 REST OF ASIA PACIFIC 363
9.5 LATIN AMERICA 369
9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 375
9.5.2 BRAZIL 376
9.5.2.1 Growing life sciences and pharmaceutical industry to fuel demand for synthetic biological products 376
9.5.3 MEXICO 381
9.5.3.1 Increasing support for biotechnology infrastructure development to augment market growth 381
9.5.4 REST OF LATIN AMERICA 386
 
9.6 MIDDLE EAST 391
9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 397
9.6.2 GCC COUNTRIES 398
9.6.2.1 KSA 403
9.6.2.2 UAE 409
9.6.2.3 Rest of GCC countries 414
9.6.3 REST OF MIDDLE EAST 419
9.7 AFRICA 424
9.7.1 AFRICA: MACROECONOMIC OUTLOOK 429
10 COMPETITIVE LANDSCAPE 431
10.1 OVERVIEW 431
10.2 KEY PLAYER STRATEGY/RIGHT TO WIN 431
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN
SYNTHETIC BIOLOGY MARKET 432
10.3 REVENUE ANALYSIS 433
10.4 MARKET SHARE ANALYSIS 434
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 436
10.5.1 STARS 436
10.5.2 EMERGING LEADERS 436
10.5.3 PERVASIVE PLAYERS 436
10.5.4 PARTICIPANTS 437
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 438
10.5.5.1 Company footprint 438
10.5.5.2 Region footprint 439
10.5.5.3 Tool footprint 439
10.5.5.4 Technology footprint 440
10.5.5.5 Application footprint 441
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 442
10.6.1 PROGRESSIVE COMPANIES 442
10.6.2 RESPONSIVE COMPANIES 442
10.6.3 DYNAMIC COMPANIES 442
10.6.4 STARTING BLOCKS 442
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 444
10.7 COMPANY VALUATION & FINANCIAL METRICS, 2023 446
10.7.1 FINANCIAL METRICS 446
10.7.2 COMPANY VALUATION 446
10.8 BRAND/PRODUCT COMPARISON 447
10.9 COMPETITIVE SCENARIO 448
10.9.1 PRODUCT LAUNCHES 448
10.9.2 DEALS 449
10.9.3 EXPANSIONS 450
11 COMPANY PROFILES 452
11.1 KEY PLAYERS 452
11.1.1 THERMO FISHER SCIENTIFIC INC. 452
11.1.1.1 Business overview 452
11.1.1.2 Products/Services offered 453
11.1.1.3 Recent developments 455
11.1.1.3.1 Product launches 455
11.1.1.3.2 Deals 455
11.1.1.3.3 Expansions 456
11.1.1.4 MnM view 456
11.1.1.4.1 Key strengths 456
11.1.1.4.2 Strategic choices 456
11.1.1.4.3 Weaknesses & competitive threats 457
11.1.2 MERCK KGAA 458
11.1.2.1 Business overview 458
11.1.2.2 Products/Services offered 459
11.1.2.3 Recent developments 461
11.1.2.3.1 Deals 461
11.1.2.4 MnM view 461
11.1.2.4.1 Key strengths 461
11.1.2.4.2 Strategic choices 462
11.1.2.4.3 Weaknesses & competitive threats 462
11.1.3 NOVOZYMES A/S 463
11.1.3.1 Business overview 463
11.1.3.2 Products/Services offered 464
11.1.3.3 Recent developments 465
11.1.3.3.1 Product launches 465
11.1.3.3.2 Deals 466
11.1.3.4 MnM view 467
11.1.3.4.1 Key strengths 467
11.1.3.4.2 Strategic choices 467
11.1.3.4.3 Weaknesses & competitive threats 467
11.1.4 EUROFINS SCIENTIFIC 468
11.1.4.1 Business overview 468
11.1.4.2 Products/Services offered 469
11.1.5 AGILENT TECHNOLOGIES INC. 471
11.1.5.1 Business overview 471
11.1.5.2 Products/Services offered 472
11.1.5.3 Recent developments 474
11.1.5.3.1 Products launches 474
11.1.5.3.2 Deals 474
11.1.5.3.3 Expansions 475
11.1.6 AMYRIS, INC. 476
11.1.6.1 Business overview 476
11.1.6.2 Products/Services offered 476
11.1.6.3 Recent developments 477
11.1.6.3.1 Deals 477
11.1.7 CODEXIS, INC. 478
11.1.7.1 Business overview 478
11.1.7.2 Products/Services offered 479
11.1.7.3 Recent developments 481
11.1.7.3.1 Product launches 481
11.1.7.3.2 Deals 481
11.1.7.3.3 Expansions 482
11.1.8 TWIST BIOSCIENCE 483
11.1.8.1 Business overview 483
11.1.8.2 Products/Services offered 484
11.1.8.3 Recent developments 485
11.1.8.3.1 Product launches 485
11.1.8.3.2 Deals 487
11.1.8.3.3 Expansions 488
11.1.9 GENSCRIPT 489
11.1.9.1 Business overview 489
11.1.9.2 Products/Services offered 490
11.1.9.3 Recent developments 492
11.1.9.3.1 Product launches 492
11.1.9.3.2 Deals 493
11.1.9.3.3 Other developments 493
11.1.10 PRECIGEN 494
11.1.10.1 Business overview 494
11.1.10.2 Products/Services offered 495
11.1.11 GINKGO BIOWORKS 497
11.1.11.1 Business overview 497
11.1.11.2 Products/Services offered 498
11.1.11.3 Recent developments 499
11.1.11.3.1 Product launches 499
11.1.11.3.2 Deals 499
11.1.12 VIRIDOS 503
11.1.12.1 Business overview 503
11.1.12.2 Products/Services offered 504
11.1.12.3 Recent developments 505
11.1.12.3.1 Product launches 505
11.1.12.3.2 Deals 507
11.1.12.3.3 Other developments 508
11.1.13 SYNTHEGO 509
11.1.13.1 Business overview 509
11.1.13.2 Products/Services offered 509
11.1.13.3 Recent developments 511
11.1.13.3.1 Product launches 511
11.1.13.3.2 Deals 512
11.1.13.3.3 Expansions 512
11.1.14 CREATIVE ENZYMES 513
11.1.14.1 Business overview 513
11.1.14.2 Products/Services offered 513
11.1.15 CYRUS BIOTECHNOLOGY 515
11.1.15.1 Business overview 515
11.1.15.2 Products/Services offered 515
11.1.15.3 Recent developments 516
11.1.15.3.1 Deals 516
11.2 OTHER PLAYERS 517
11.2.1 ATUM 517
11.2.2 TESELAGEN 518
11.2.3 ARZEDA 519
11.2.4 INTEGRATED DNA TECHNOLOGIES, INC. 520
11.2.5 NEW ENGLAND BIOLABS 522
11.2.6 ELEVATEBIO 523
11.2.7 ZENFOLD (IOSYNTH) 524
11.2.8 SYNBIO TECHNOLOGIES 525
11.2.9 INSCRIPTA, INC. 526
11.2.10 CRISPR THERAPEUTICS 526
12 APPENDIX 527
12.1 DISCUSSION GUIDE 527
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 533
12.3 CUSTOMIZATION OPTIONS 535
12.4 RELATED REPORTS 535
12.5 AUTHOR DETAILS 536